Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Despite improved rates of remission and cure in newly diagnosed adult acute lymphoblastic leukemia (ALL), the prognosis for patients with relapsed or refractory disease remains poor and the 5-year overall survival rate after relapse is under 10%. A recent paradigm shift has focused on the promise of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yurkiewicz, Ilana R, Muffly, Lori, Liedtke, Michaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063246/
https://www.ncbi.nlm.nih.gov/pubmed/30087554
http://dx.doi.org/10.2147/DDDT.S150317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063246/
https://www.ncbi.nlm.nih.gov/pubmed/30087554
http://dx.doi.org/10.2147/DDDT.S150317

Ejemplares similares